INTRODUCTION
Febuxostat chemically is 2-[3-cyano-4-(2-methlypropo xy) phenyl] -4-methlythiazole -5 -carbo xylic acid 1 (Figure 1 ). It is a non purine selective inhib itor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout. In contrast to allopurinol, febuxostat inhibits both oxidized and reduced forms of xanthine o xidase and has min imal effects on other enzy mes of purine and pyrimid ine metabolis m 3, 4. A study comparing febuxostat to allopurinol found that more individuals treated with febu xostat had decreased levels of uric acid, but there was no difference in the amount of initial gout flares or the surface area of gout tophi 2 .
Ketorolac tromethamine
Systematic (IUPAC) name: (±)-5-benzoyl-2, 3-dihydro-1H-pyrrolizine-1-carbo xylic acid, 2-amino-2 (hydroxy methyl)-1, 3- In this paper we reported a sensitive liquid chromatographic method with wide linearity range, good resolution where running time is less than 10 mins. The method has been validated as per the ICH guidelines 15 -16 and can be successfully applied to pharmaceutical formulat ions.
ABS TRACT
A simple, fast, precise, selective and accurate RP-HPLC method was developed and validated for the simultaneous determination of Febuxostat and Ketorolac from bulk and formulations. Chromatographic separation was achieved isocratically on a Waters C 18 column (250×4.6 mm, 5 µ particle size) using a mobile phase, M ethanol and Ammonium acetate buffer (adjusted to pH 6.0 with 1% orthophosphoric acid) in the ratio of 60:40. The flow rate was 1 ml/min and effluent was detected at 321nm. The retention time of Febuxostat and Ketorolac were 2.62 min and 3.96 min. respectively. Linearity was observed in the concentration range of 5-30µg/ml and 10-60 µg/ml for Febuxostat and Ketorolac respectively with correlation coefficient 0.999 for both the drugs. Percent recoveries obtained for both the drugs were 99.94-99.22% and 99.44-101.06%, respectively. The method was validated according to the ICH guidelines with respect to specificity, linearity, accuracy, precision and robustness. The method developed can be used for the routine analysis of Febuxostat and Ketorolac from their combined dosage form. 
MATERIALS AND METHODS

Reagents and chemicals
Methanol HPLC grade was procured fro m E.Merck Ltd, Mumbai. Methanol, orthophosphoric acid, A mmon iu m acetate buffer AR grade were procured fro m S.D. fine chemicals, Hyderabad. Water HPLC grade was prepared using Millipore purification system. Febu xostat and Keterolac reference standards procured fro m Dr.Reddy's laboratories, Hyderabad.
Instrumentation
The HPLC system consists of water Empo wer 2487 having photodiode array detector system, wh ich was connected with the help of Empower-2 software for data integration and processing. Inertsil ODS-3V (250 X 4.6 mm) 5μ column was used for the analysis.
HPLC conditions
The contents of the mobile phase were Methanol and Ammoniu m acetate buffer (adjusted to pH 6.0 with 1% orthophosphoric acid) in the ratio of 60:40. These were filtered through 0.45μ memb rane filter and degassed by sonication before use. The flow rate of mobile phase was optimized to 1.0 ml / min. The run time was set at 10 min and column temperature was maintained at ambient. The volume of in jection was 10μl, and the eluent was detected at 321nm. Each of standard and test preparations was injected into the column and the responses recorded ( Figure 3 and 4) .
MET HOD
The RP-HPLC Method of Febuxostat and Ketorolac were achieved by isocratic elution technique with UV -VIS Detector. FBT and KTC were determined at 321n m respectively with the concentration range of 5-30 g/ ml for FBT and 10-60 g/ ml fo r KTC respectively. fig.03 &04. For analysis of tablet formulat ion, the tablet powder equivalent to 25 mg was taken, dissolved in 25 ml volumetric flask and made up to 25ml with Methanol. The solution was sonicated for 15min, centrifuged at 100 rp m for 15 min and filtered through Whatmann filter paper No.41. Fro m clear solution, further dilutions were made to get 10 g/ ml of FBT and KTC theoretically.
Preparation of standard stock solution
Standard stock solutions Febuxostat and Ketorolac of strength 1mg/ml were prepared using dichloromethane. Appropriate amounts of these stock solutions were then further diluted to get the required concentrations of standard stock solutions. 
System suitability studies
The resolution, number of theoretical plates, retention time and peak asymmetry were calculated for the working standard solutions and is as shown in Table 1 .
The values obtained demonstrated the suitability of the system for the analysis of these drugs in combination. The typical chromatogram of standard solution is as shown in Figure 3 . For recovery studies, to the reanalyzed formulation, solutions of raw material containing different concentrations were added and the amount of drug recovered was calculated.
The procedure was repeated as per the analysis of formulat ion. The amount of drug recovered was calculated by using slope and intercept values from the calibrat ion graph. Finally the method was validated as per ICH guide lines for precision, accuracy, specificity, linearity, reproducibility, limit of detection and limit of quantification.
MET HOD VALIDATION
As per ICH guidelines, the method validation parameters checked were specificity, linearity, precision, accuracy, limit of detection, limit of quantitation and robustness.
Specificity
A blank solution (mob ile phase) was injected and the chromatogram showed no inferring peaks at retention time of the two drugs. The chromatogram of Febu xostat and Ketorolac extracted fro m the tablet were co mpared with those acquired fro m Febu xostat and Ketorolac standards, correlation was good (in terms of tR and area) indicates specificity of method. Co mmon tablet excip ients like starch, lactose, magnesium stearate were dispers ed in dichloro methane, filtered and in jected. There was no interference found.
Linearity and range
Aliquots of standard stock solutions of Febuxostat and Ketorolac were taken in 10 ml volu metric flasks and diluted with dichloro methane to get final concentrations in range of 5-30μg/ ml for Febu xostat and 10-60μg/ ml for Ketorolac. Triplicate in jections were made five t imes for each concentration for each drug separately and chromato graphed under the conditions as described above. The plots of peak area versus respective concentrations of Febuxostat and Ketorolac were found to be linear in the concentration range of 5-30μg/ ml and 10-60μg/ ml respectively. The linear regression equations of the lines are: 
Precision
Precision study was performed to find out intra-day and inter-day variations. The percent relative standard deviation for intra-day precision was 0.288% for Febuxostat and 0.232% for and Ketorolac and inter-day precision was 1.137% for Febu xostat and 1.323% for Ketorolac. Both the values were well within the limit of 2% as per ICH guidelines.
Accuracy
The accuracy was determined by recovery studies. The recovery studies were performed by standard addition me thod, at 80%, 100%, 120% level. Percent recovered was calculated using regression equation. For both the drugs, recovery was performed in same way and in triplicate. The percentage recovery were calculated and presented in Table 3 .
Li mit of detection and limit of quantitation
The limit of detection (LOD) is the smallest concentration that can be detected but not necessarily quantified as an exact value.
LOD = 3.3 X Standard deviation of y intercept
Slope of calib ration curve
The LOQ is the lowest amount of analyte in the sample that can be quantitatively determined with suitable precision and accuracy. 
RES ULTS AND DISCUSS ION
The proposed method was found to be simple and sensitive with linearity in the concentration range of 5 to 30μg/ ml for Febu xostat and 10 to 60μg/ ml for Ketorolac. The method was found to be accurate and precise as indicated by results of recovery studies and %RSD not more than 2%. LOD and LOQ for Febu xostat were found to be 0.23μg/ ml and 0.87μg/ml respectively and for Ketorolac were 1.13μg/ ml and 3.03μg/ ml respectively. The proposed method was found to be specific as there is no interference fro m co mmon tablet excip ients like lactose, starch etc. 
CONCLUS ION
The results of the analysis of pharmaceutical dosage forms by the proposed methods are highly reproducible, reliable, and are in good agreement with the label claims of the drug. The additives usually present in the pharmaceutical formu lations of the assayed samples did not interfere with Febu xostat and Ketorolac. It may be said that the proposed methods are precise, sensitive, and accurate, so that these can be used as standard pharmacopoeial methods for the simultaneous determination of Febuxostat and Ketorolac in tablets using the HPLC systems. The advantages of the proposed method involve a simple procedure for sample preparation and relatively short time of analysis. Apart from this, it can be used for assays of Febuxostat and Ketorolac in bio logical fluids or in pharmacokinetic investigations.
